InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: None

Monday, 01/30/2023 11:59:18 AM

Monday, January 30, 2023 11:59:18 AM

Post# of 575
Two observations from todays PR. First the 40mg response was in Wild Type Flt-3 patient. A triple combination in Wild-Type Flt-3 first line AML would be a major market. So this is very encouraging. It would not compete with the Flt-3mut triplet combinations. Second. APTO believes that Tuspetinib is active in sub-saturating doses because of it multi-kinase profile. This is key to its activity at these low doses and makes TUSP a very good combination partner.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News